MD Anderson and CureVac collaborate to develop mRNA cancer vaccines

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD Anderson Cancer Center and CureVac N.V. are entering a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Lauren Averett Byers, professor of thoracic/head & neck medical oncology at the University of Texas MD Anderson Cancer Center, received the 2025 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology. The award recognizes her fundamental discoveries and contributions to identifying novel therapeutic strategies for small cell lung cancer, which have paved the way for personalized treatments, even in the most highly recalcitrant cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login